Evidence map›Paper›PMID 37581593›Full record

Trial reportBlood advances2023

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.

Adam J Olszewski, Tycel J Phillips, Marc S Hoffmann, Philippe Armand, Tae Min Kim, Dok Hyun Yoon, Amitkumar Mehta, Richard Greil, Jason Westin, Izidore S Lossos and 8 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03677141 (A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab), which is not on this map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03677141 phase1 / phase2completednot on this map

A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma

TypeinterventionalSponsorHoffmann-La RocheRan2019 to 2023Enrolled117ConditionsB-cell Non-Hodgkin LymphomaArmsMosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. A Comprehensive Meta-Analysis of the Cardiovascular Adverse Effects of Bispecific Antibody Therapy in Hematologic Malignancies.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Adam J OlszewskiLifespan Cancer Institute, Warren Alpert Medical School of Brown University, Providence, RI.ORCID 0000-0002-6472-6658
Tycel J PhillipsDivision of Hematology and Oncology, University of Michigan, Ann Arbor, MI.ORCID 0000-0003-2143-9672
Marc S HoffmannHematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Kansas City, KS.
Philippe ArmandDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Tae Min KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.ORCID 0000-0001-6145-4426
Dok Hyun YoonAsan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Amitkumar MehtaDivision of Hematology and Oncology, University of Alabama School of Medicine, Birmingham, AL.ORCID 0000-0003-0537-4207
Richard GreilIIIrd Medical Department, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Paracelsus Medical University, Salzburg, Austria.
Jason WestinDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-1824-2337
Izidore S LossosDivision of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL.ORCID 0000-0002-9346-9013
Javier L MunozBanner MD Anderson Cancer Center, Gilbert, AZ.ORCID 0000-0002-9060-8911
Jason SitGenentech, Inc., South San Francisco, CA.
Michael C WeiGenentech, Inc., South San Francisco, CA.
Annie YangGenentech, Inc., South San Francisco, CA.
Vivian ChenGenentech, Inc., South San Francisco, CA.
Enkhtsetseg PurevGenentech, Inc., South San Francisco, CA.
Donald L YeeGenentech, Inc., South San Francisco, CA.
Ulrich JaegerDepartment of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-9826-1062

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to or relapse after first-line therapy, highlighting the need for better treatments. Mosunetuzumab is a CD20 × CD3 bispecific antibody that engages and redirects T cells to eliminate malignant B cells. In this phase 2, open-label study (NCT03677141), 40 patients (52.5% with international prognostic index ≥3) with previously untreated DLBCL initiated 6 cycles of IV mosunetuzumab with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Mosunetuzumab was administered in cycle 1 as step-up doses to mitigate cytokine release syndrome [CRS], and a dose of 30 mg was given on day 1 of cycles 2-6. Efficacy end points included objective and complete response rates, as determined by the investigator, via positron emission tomography-computed tomography, using Lugano 2014 criteria (87.5% and 85.0%, respectively). At a median follow-up of 32.0 months, the estimated 2-year progression-free survival and event-free survival rates were 65.4% (95% confidence interval [CI], 49.5-81.4) and 60.4% (95% CI, 44.7-76.1), respectively. CRS occurred in 60.0% of patients; all events were grade 1 (45.0%) or grade 2 (15.0%) and occurred primarily in cycle 1. Mosunetuzumab-related grade ≥3 neurologic adverse events (AEs) potentially consistent with immune effector cell-associated neurotoxicity syndrome occurred in 1 patient (2.5%). Grade 5 AEs were reported in 2 patients. Neutropenia occurred in 70.0% of patients, mostly during cycle 1 and was of short duration. These findings demonstrate promising activity and a manageable safety profile for mosunetuzumab-CHOP and warrant further investigation of mosunetuzumab in first-line combination regimens for DLBCL.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseAntineoplastic AgentsHumansNeoplasm Recurrence, LocalNeurotoxicity SyndromesAntineoplastic Agentscell-associated neurotoxicity

Identifiers

PMID37581593
PMCPMC10582312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.